Huons Group has unveiled significant strides in its research and development (R&D) endeavors as it gears up for future expansion.
Huons has taken the initiative in enhancing convenience for diabetes patients, in alignment with the government’s latest health insurance support policies.
Local biomanufacturing and health care company Huons will donate 6,000 glucose monitoring devices to a local community for diabetic patients.
Huons Group is solidifying its global presence as it continues to achieve its highest performance.
Huons is acquiring Crystal Life Sciences from its parent company, CG Invites.
Huons’ Quisqualis Extract Powder, targeting middle-aged men's prostate-related diseases, has become a proven option supported by academic research.
Huons Global saw an on-year surge in its Q3 operating profits, driven by strong growth from subsidiaries Huons, Humedix, and HuM&C.
Huonslab's HLB3-002, a human genetic recombinant hyaluronidase candidate, produced meaningful results confirming its efficacy, the Korean company said Tuesday.
Huons is pursuing an ambitious blueprint to expand within high-growth sectors with the goal of achieving one trillion won ($750 million) in sales.
Huons is entering the U.S. health functional food market with their Quisqualis Extract Powder, targeting customers concerned about their prostate health.
Korea JoongAng Daily Sitemap